The new diabetes test helps identify patients with type 1 diabetes The FDA has approved empagliflozin/linagliptin tablets as an adjunct to diet and exercise to ...

Ingelheim, Germany and Indianapolis, US, 16 September, 2014 – Boehringer Ingelheim and Eli Lilly and Company today presented results from a 52-week Phase III study ...

The investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in patients with type 2 diabetes as presented by Boehringer Ingelheim and Eli Lilly and Company at ...

Glyxambi Approved for Type 2 Diabetes The Food and Drug Administration (FDA) has approved Glyxambi (empagliflozin/linagliptin tablets; Boehringer Ingelheim and Eli ...

GLYXAMBI is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. GLYXAMBI has not been studied in patients with a history of pancreatitis, and it is unknown ...

Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (FDA) for empagliflozin and linagliptin tablets, 10 mg/5 mg and 25 mg/5 mg (USRLD: ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Whether already on metformin or ...

Oral semaglutide, a tablet-based GLP-1 receptor agonist drug, has performed stronger in achieving weight loss and reduction in HbA1c than empagliflozin in a new trial. The results come from the ...

RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 -- Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults ...

- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs. empagliflozin or ...